The American Association for Cancer Research (AACR) meeting is held in April each year and is a major international forum for preclinical cancer research. The abstracts of presentations are out and two are related to SNTA's HSP90 inhibitor ganetespib (aka STA-9090). Click on the link to be taken to the full abstract
#2677: Novel Hsp90 inhibitor, STA-9090, for combination with radiotherapy
Conclusion: "Monotherapy treatment with either STA-9090 or 2 Gray (Gy) ionizing irradiation resulted in moderate reductions in human tumor growth rates in a mouse xenograft model. Combination of STA-9090 with 2 Gy irradiation resulted in substantial tumor regression. Increasing the dose of radiation in the combination arm to 4 Gy further enhanced tumor regression, resulting in a 50% reduction in tumor volume. In summary, STA-9090 offers a safe and effective strategy for improving the outcome of radiotherapy in human cancers."
#1638: Potent anticancer actions of the Hsp90 inhibitor STA-9090 in wild-type EGFR models of lung cancerConclusion: "Inhibition of Hsp90 activity therefore presents a promising approach for combating NSCLC induced by mutations in genes other than EGFR, as well as by compensatory pathways upregulated in the context of EGFR-inhibitor resistance."Note that the results of the second abstract listed correlate to the preliminary NSCLC data seen with this drug- the best results have been seen in the wild-type arm of the trial that has since been expanded. SNTA has also expanded the trial to include other protein mutations (details not yet disclosed)I am in the process of updating the SNTA research page with all the information from the two press releases put out by SNTA this weekend- should be complete soon.
#2677: Novel Hsp90 inhibitor, STA-9090, for combination with radiotherapy
Conclusion: "Monotherapy treatment with either STA-9090 or 2 Gray (Gy) ionizing irradiation resulted in moderate reductions in human tumor growth rates in a mouse xenograft model. Combination of STA-9090 with 2 Gy irradiation resulted in substantial tumor regression. Increasing the dose of radiation in the combination arm to 4 Gy further enhanced tumor regression, resulting in a 50% reduction in tumor volume. In summary, STA-9090 offers a safe and effective strategy for improving the outcome of radiotherapy in human cancers."
#1638: Potent anticancer actions of the Hsp90 inhibitor STA-9090 in wild-type EGFR models of lung cancerConclusion: "Inhibition of Hsp90 activity therefore presents a promising approach for combating NSCLC induced by mutations in genes other than EGFR, as well as by compensatory pathways upregulated in the context of EGFR-inhibitor resistance."Note that the results of the second abstract listed correlate to the preliminary NSCLC data seen with this drug- the best results have been seen in the wild-type arm of the trial that has since been expanded. SNTA has also expanded the trial to include other protein mutations (details not yet disclosed)I am in the process of updating the SNTA research page with all the information from the two press releases put out by SNTA this weekend- should be complete soon.
RSS Feed
